Potential future uses of calcimimetics in patients with chronic kidney disease

NDT Plus

Volumn 1, Issue SUPPL.1, 2008, Pages

  Chonchol, Michel ^a   Wüthrich, Rudolf P ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Chronic kidney disease; Persistent hyperparathyroidism; Renal transplant

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; VITAMIN D;

BONE DISEASE; CALCIFICATION; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DIARRHEA; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MYALGIA; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 39349110000     PISSN: 17530784     EISSN: 17530792     Source Type: Journal    
DOI: 10.1093/ndtplus/sfm043     Document Type: Conference Paper

References (43)

1. Kausz AT, Guo H, Pereira BJ et al. General medical care among patients with chronic kidney disease: Opportunities for improving outcomes. J Am Soc Nephrol 2005; 16: 3092-3101
2. Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: A single-centre study. Niphrol Dial Transplant 2004; 19: 1281-1287
3. Cundy T, Kanis JA, Heynen G et al. Calcium metabolism and hyperparathyroidism after renal transplantation. Q J Med 1983; 52: 67-78
4. Lobo PI, Cortez MS, Stevenson W et al. Northocalcemic hyper-parathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol. Clin Transplant 1995; 9: 277-281
5. Keith DS, Nichols GA, Gullion CM et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004; 164: 659-663
6. K/DOQI Guidelines 2003. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201
7. De Boer IH, Gorodetskaya I, Young B et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769
8. Coen G, Ballanti P, Bonucci E et al. Renal osteodystrophy in pre-dialysis and hemodialysis patients: Comparison of histologic patterns and diagnostic predictivity of intact PTH. Nephron 2002; 91: 103-111
9. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44: 1024-1030
10. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
11. Block GA. The impact of calcimimetics on mineral metabolism and secondary hyperparathyroidism in end-stage renal disease. Kidney Int Suppl 2003: S131-S136
12. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
13. Spiegel D, Raggi P, Mehta R et al. Coronary and aortic calcifications in patients new to dialysis. Hemodial Int 2004; 8: 265-272
14. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
15. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19(Suppl 5): V2-V8
16. Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005; 46: 58-67
17. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
18. Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 2005; 16: 800-807
19. Lindberg JS, Moe SM, Goodman WG et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium × phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254
20. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193
21. Torres A, Rodriguez AP, Concepcion MT et al. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations. Nephrol Dial Transplant 1998; 13(Suppl 3): 94-97
22. Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998; 13: 436-442
23. Hernandez D, Rufino M, Bartolomei S et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int 2005; 67: 2015-2020
24. Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: Causes and clinical implications. Am J Tansplant 2005; 5: 1934-1941
25. Brandenburg VM, Westenfeld R, Ketteler M. The fate of bone after renal transplantation. J Nephrol 2004; 17: 190-204
26. Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998; 54: 1704-1713
27. Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59: 1187-1201
28. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003; 14: 2669-2676
29. Lee PP, Schiffmann L, Offermann G et al. Effects of parathyroidectomy on renal allograft survival. Kidney Blood Press Res 2004; 27: 191-196
30. Garcia A, Mazuecos A, Garcia T et al. Effect of parathyroidectomy on renal graft function. Transplant Proc 2005; 37: 1459-1461
31. Schwarz A, Rustien G, Merkel S et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22: 584-591.
32. Rostaing L, Moreau-Gaudry X et al. Changes in blood pressure and renal function after subtotal parathyroidectomy in renal transplant patients presenting persistent hypercalcemic hyperparathyroidism. Dansplant Proc 1997; 29: 204-206
33. Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2006; 22: 577-583
34. Apostolou T, Damianou L, Kotsiev V et al. Treatment of severe hyperacalcemia due to refractory hyperparathyroidism in renal transplant patients with the calcimimetic agent cinacalcet. Clin Nephrol 2006; 65: 374-377
35. Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82: 675-680
36. Kruse AE, Eisenberger U, Frey FJ et al, The calcimimetic cinacalcet normalizes scrum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1311-1314
37. Leca N, Lafttavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant tested with cina6alcet. Am J Transplant 2006; 6: 2391-1395
38. Serra AL, Schwarz AA, Wick FH et al. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephral Dial Transsplant 2005; 20: 1315-1319
39. Apostolou T, Kollia K, Damianou L et al. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet. Transplant Proc 2006; 38: 3514-3516
40. Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006; 1: 323-326
41. El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007; 83: 546-549
42. Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG Q73 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-583
43. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771